The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1468
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Peginterferon Beta-1a (Plegridy) for Multiple Sclerosis

The FDA has approved a pegylated form of interferon beta-1a (Plegridy – Biogen) for biweekly treatment of patients with relapsing multiple sclerosis (MS).

STANDARD TREATMENT — FDA-approved drugs for treatment of relapsing-remitting MS are listed in Table 2. Interferon beta (Avonex, and others) and glatiramer acetate (Copaxone, Glatopa), both of which must be injected, are generally used first. They reduce clinical relapse rates by about 30% and decrease the number of brain lesions seen on MRI.1

Second-line drugs are usually reserved for patients with severe disease and for those who cannot take first-line drugs. Natalizumab (Tysabri), an IV recombinant humanized monoclonal antibody, can decrease relapse frequency and slow progression of the disease. Alemtuzumab, an IV anti-CD52 monoclonal antibody, is now approved ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1468
 Downloadable, electronic issue - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian